Popular on Amzeal
- Gamma Tech Services named to 2026 MSP 501 list of top managed services providers - 433
- WOWX Completes Its Transition from CEX to Decentralized Derivatives Infrastructure - 408
- RAS AP Consulting Issues National Compliance Alert and Launches Q4 2026 AP Readiness Program Ahead of IRS FIRE → IRIS Cutover - 399
- Tulsa Air & Space Museum Launches "Give $16 for the F-16" Challenge to Bring Thunderbird Home for Veterans Day - 387
- Coinfiliate Launches Platform to Helps Shoppers Earn Cashback and Creators Earn Referral Rewards - 364
- Industrial & systems engineering educator and professional to lead global strategic partnerships for professional society - 349
- Pregis Launches Sharp InfinX: On-Demand Rightsized Mailing System Delivering a Precision-Sized Mailer for Every Order - 346
- RAW Social Reports Surpassing 2 Billion Platform Users as Global Engagement Continues to Expand - 342
- Geospatial Innovation Comes to Sacramento: FOSS4G NA 2026 - 333
- Gen Z entrepreneur Darian Crisp builds creator tech, joins REVOLT's "Bet on Black" - 316
Similar on Amzeal
- AthleteMerch.com Surpasses 100,000 Custom Items Delivered to Fans Nationwide
- Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
- New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
- Longevity Academy Features Gail Humble, MD of KLOTHO SKIN in the Longevity Leaders Project
- Expanding Into Medically Supervised Wellness With Major Apollo Wellness Centers Announcement; Sibannac, Inc. (Stock Symbol: SNNC)
- Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Win Gold in Raleigh's Best Awards for Second Consecutive Year
- Mr Hospital Bed Cites Hill Rom Hospital Bed Models Best Value Home Care Hospital Beds 2026
- Hospital Direct Medical Equipment Company Seeing Growth in Used Refurbished Medical Equipment Sales
- Soft & Sweet Unveils New Studio Location and Website for All-Natural Sugaring in Las Vegas
- National Literacy and Workforce Readiness Crisis Sparks New Program Launching in Birmingham
ClearSight Therapeutics Receives U.S. Patent Notice of Allowance
Amzeal News/10644298
USPTO allows 26 claims for ophthalmic formulations containing quaternary chitosan derivatives, marking a key step toward U.S. patent protection.
DALLAS - Amzeal -- ClearSight Therapeutics Receives U.S. Patent Notice of Allowance for Ophthalmic Formulation Technology for unmet ocular diseases
Allowance marks an intellectual property milestone for innovative biopolymeric formulations developed for ocular applications
DALLAS, TX — [Release Date] — ClearSight Therapeutics today announced receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 19/380,414, titled "Ophthalmic Solution Containing Quaternary Chitosan Derivatives for Treating Ocular Diseases."
The notice, mailed September 29, 2026, allows 26 claims, including composition and method claims. The allowance represents an important step toward securing U.S. patent protection for ClearSight's ophthalmic formulation technology.
More on Amzeal News
"This allowance marks an important milestone for ClearSight and the science behind our ophthalmic formulations," said Patrick Smale, co-founder and CEO of ClearSight Therapeutics. "Building a strong intellectual property foundation supports our mission to develop innovative, accessible eye care solutions. We're encouraged by this progress as we continue advancing our technology."
"The formulation work focused on preserving the efficacy and key properties of quaternary chitosan in an ophthalmic solution," said co-inventor Nuria Jimenez, PhD, and co-founder & co-inventor Suchismita Acharya, PhD. "We're pleased that the examiner recognized the stability and antiviral activity data presented in the application, and we look forward to building on this scientific foundation to develop our eyedrop product to help people and expand our patent portfolio."
In its statement of reasons for allowance, the examiner cited evidence of acceptable formulation stability, preserved antiviral activity, and unexpectedly higher antiviral activity at 8- and 24-hour time points. These findings relate to evidence presented during patent examination and do not establish clinical efficacy or regulatory approval.
More on Amzeal News
About ClearSight Therapeutics
ClearSight Therapeutics is a Dallas/Fort Worth-based company founded in 2023 by eye care industry veterans and partners to develop better solutions for common eye conditions. The company is advancing next-generation over-the-counter ophthalmic products designed to address dryness, irritation, and ocular discomfort. For more information, visit clearsighttx.com.
Media Contact
ClearSight Therapeutics
info@clearsighttx.com
972-983-7761
Allowance marks an intellectual property milestone for innovative biopolymeric formulations developed for ocular applications
DALLAS, TX — [Release Date] — ClearSight Therapeutics today announced receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 19/380,414, titled "Ophthalmic Solution Containing Quaternary Chitosan Derivatives for Treating Ocular Diseases."
The notice, mailed September 29, 2026, allows 26 claims, including composition and method claims. The allowance represents an important step toward securing U.S. patent protection for ClearSight's ophthalmic formulation technology.
More on Amzeal News
- Decode Digital Works Launches Independent Technology Evaluation Practice
- Tampa Holiday Sessions: Captured by Mallary Opens 2026 Christmas Minis With Two New Sets
- Tampa Web Design Launches New Website for Entrepreneur and Capital Markets Advisor Martin Sumichrast
- Content Catalyst launches Gateway Catalyst, governed AI access for analyst firms' research
- Miami Dade College and World Affairs Council of Miami announce Navarro-Cabrera scholarship
"This allowance marks an important milestone for ClearSight and the science behind our ophthalmic formulations," said Patrick Smale, co-founder and CEO of ClearSight Therapeutics. "Building a strong intellectual property foundation supports our mission to develop innovative, accessible eye care solutions. We're encouraged by this progress as we continue advancing our technology."
"The formulation work focused on preserving the efficacy and key properties of quaternary chitosan in an ophthalmic solution," said co-inventor Nuria Jimenez, PhD, and co-founder & co-inventor Suchismita Acharya, PhD. "We're pleased that the examiner recognized the stability and antiviral activity data presented in the application, and we look forward to building on this scientific foundation to develop our eyedrop product to help people and expand our patent portfolio."
In its statement of reasons for allowance, the examiner cited evidence of acceptable formulation stability, preserved antiviral activity, and unexpectedly higher antiviral activity at 8- and 24-hour time points. These findings relate to evidence presented during patent examination and do not establish clinical efficacy or regulatory approval.
More on Amzeal News
- NASA Space Apps Yonkers Appoints Dmitriy Malygin as Judge in 2026
- Bridging Canvas and Cosmos: How Bioengineer Farin DeBose Captured the Essence of "True Science"
- Service Stories Launches First Auto Repair SEO Platform to Turn Repair Orders Into AI Search Leads
- RPP to host first Professional Padel Week in Miami and announce the 2026 USA Awards winners
- UK Financial Ltd. Announces Maya Preferred PRA as First Fully Verified Asset on MAYA CHAIN; Chainlink Proof of Reserve Integration Planned for Network
About ClearSight Therapeutics
ClearSight Therapeutics is a Dallas/Fort Worth-based company founded in 2023 by eye care industry veterans and partners to develop better solutions for common eye conditions. The company is advancing next-generation over-the-counter ophthalmic products designed to address dryness, irritation, and ocular discomfort. For more information, visit clearsighttx.com.
Media Contact
ClearSight Therapeutics
info@clearsighttx.com
972-983-7761
Source: ClearSight Therapeutics, Inc.
0 Comments
Latest on Amzeal News
- Immerse Yourself in the Historic Tochigi Autumn Festival, Celebrated Every Two Years Since 1874
- Former Texas Longhorn Launches Innrcirql, Creator Platform Where Fans Open Packs Instead of Paying
- Can You Spot the Next Trillion-Dollar Company? Blueshift Launches Global Prediction Challenge
- Our Lady of the Artilects Author Andrew Gillsmith Featured in America Weekly on Catholic Storytelling and AI
- Resident Inspect Expands Virtual Property Inspections With AppFolio and Rentvine Integrations
- XImagineAI Upgrades Its Multi-Model AI Video Generator for Image to Video and Text to Video
- Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA)
- AeroNet Deploys netElastic vBNG and CGNAT with Tarana Wireless to Deliver Scalable, Fiber-Class Broadband Across Puerto Rico
- New Atlas Maps the 38 States Behind Every Conversation
- Atlanta Company Launches Free, Ad-Free, Nonpartisan Voter Planning App for All 50 States Ahead of the Nov. 3 Election
- VRX Racing Exhibits 2026 RTR Lineup at NRHSA Table-Top Expo
- NECP Promotes Chertova to Senior Business Analyst
- Security Industry Veteran Anthony Rumore Launches AegisLead to Help Security Companies Find Business and Manage Growth
- BinaryWorks Free Webinar Oct 29 Helps Drupal Site Owners Choose Upgrade or WordPress Before Dec 9
- Two Decades of Mathematical Research Demotes Legacy Silicon, SD-WAN, Database and Cloud C
- Phinge Discloses the Linux Foundation & the Agentic AI Foundation Have Received Formal Intellectual Property Notice & Evidence Preservation Demands
- Charlie Shaw and Patrick Carragher win SEO Agency of the Year 2026
- Canadian Woman Plants 1,667 Love Stories in a Field of Peonies That Could Bloom for 100 Years
- SDVOSBtech.com Authorized Integrator for GuardDog.ai, Bringing Advanced AI-Powered Cybersecurity
- New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)